Cargando…
The Systemic Immune Network in Recent Onset Type 1 Diabetes: Central Role of Interleukin-1 Receptor Antagonist (DIATOR Trial)
BACKGROUND: The hypothesis was tested that the systemic immune milieu in recent-onset type 1 diabetes is associated with residual beta cell function and other metabolic patient characteristics. METHODS AND FINDINGS: All patients (n = 89, 40% female) of the Diabetes and Atorvastatin (DIATOR) Trial we...
Autores principales: | Kolb, Hubert, Lückemeyer, Kathrin, Heise, Tim, Herder, Christian, Schloot, Nanette C., Koenig, Wolfgang, Heinemann, Lutz, Martin, Stephan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3753272/ https://www.ncbi.nlm.nih.gov/pubmed/23991111 http://dx.doi.org/10.1371/journal.pone.0072440 |
Ejemplares similares
-
Residual Beta Cell Function in Newly Diagnosed Type 1 Diabetes after
Treatment with Atorvastatin: The Randomized DIATOR Trial
por: Martin, Stephan, et al.
Publicado: (2011) -
Improved Preservation of Residual Beta Cell Function by Atorvastatin in Patients with Recent Onset Type 1 Diabetes and High CRP Levels (DIATOR Trial)
por: Strom, Alexander, et al.
Publicado: (2012) -
Elevated Levels of the Anti-Inflammatory Interleukin-1 Receptor Antagonist Precede the Onset of Type 2 Diabetes: The Whitehall II Study
por: Herder, Christian, et al.
Publicado: (2009) -
COVID-19-Lockdown hat die akute Inzidenz des Typ-1-Diabetes nicht beeinflusst
por: Schloot, Nanette
Publicado: (2020) -
Ketone bodies: from enemy to friend and guardian angel
por: Kolb, Hubert, et al.
Publicado: (2021)